COVID-19 Clinical Development: What's in the Pipeline to Address the SARS-CoV-2 Pandemic?

Posted by Kristyn Feldman on Tue, Mar 24, 2020

Parul Rewari, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

As nations around the globe are hit hard by the novel coronavirus pandemic, many are asking the same question: What treatments or preventions are in the pipeline that may address COVID-19? Researchers the world over have launched numerous research, preclinical and clinical-stage programs in an effort to identify vaccines and treatments that can tackle the virus or to find treatments that mediate the downstream effects of the virus.


>
Read More

Clinical Development Risks and Issues in a COVID-19 World

Posted by Jonathan Rowe on Fri, Mar 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).


>
Read More

Bringing the Customer Journey to Life

Posted by Erika Papaccioli. on Thu, Jan 16, 2020

Leslie Happas Norton and Giulia Lopomo co-wrote this blog post with Erika Papaccioli.

Great marketing is about establishing value for the customer and, ultimately, changing behavior. It’s a goal that requires a firm grounding in customer insight, which ultimately fuels memorable, impactful brand campaigns. A good example of this is the recent Chantix campaign featuring celebrity spokesperson Ray Liotta. Born out of the insight that it’s believed to be a sign of weakness to reach out for help quitting smoking, the ads juxtapose “tough guy” Liotta with the need for Chantix—showing smokers that they don’t have to quit on their own.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Jan 06, 2020

Dean Hakanson co-wrote this blog post with Ed Schoonveld. This blog post was originally published on The Price of Global Health.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

Alternate Sites of Care: The Changing Face of Healthcare Delivery

Posted by Parijat Sharma on Wed, Nov 27, 2019

Matthew Ruple co-authored this post with Parijat Sharma. This is the first in a series of blog posts on the shifting sites of care. 

A confluence of factors is driving a dramatic shift in healthcare delivery from traditional sites of care such as hospitals and clinics to outpatient and retail care sites such as urgent care clinics and ambulatory surgical centers. Of course, this shift doesn’t just change things for patients and providers. It also greatly affects the go-to-market strategies for pharmaceutical and medical device manufacturers. As the care setting evolves and diversifies, stakeholders throughout the healthcare ecosystem have to evolve in kind.


>
Read More